Back to Directory

NWPharmaTech

LondonGreater London
Founded 2021
Micellar oral cannabidiol formulation for psychiatric drug development

NWPharmaTech is a clinical-stage biotechnology company developing investigational oral cannabidiol formulations for psychiatric disorders.

Its NWPT-SM32300 programme uses a high-loading micellar softgel intended to deliver consistent oral doses. The company reports completion of a Phase 1 pharmacokinetic and tolerability study in healthy volunteers, with Phase 2b research planned. Its development activities address schizophrenia and clinical high risk of psychosis; therapeutic efficacy and regulatory approval have not been established.

BiopharmaNeurologyDrug DeliveryClinical Research
Small Molecule Drugs

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page